161 related articles for article (PubMed ID: 21610100)
1. Alterations in glycopeptides associated with herceptin treatment of human breast carcinoma mcf-7 and T-lymphoblastoid cells.
Lattová E; Bartusik D; Spicer V; Jellusova J; Perreault H; Tomanek B
Mol Cell Proteomics; 2011 Sep; 10(9):M111.007765. PubMed ID: 21610100
[TBL] [Abstract][Full Text] [Related]
2. N-glycomic changes in human breast carcinoma MCF-7 and T-lymphoblastoid cells after treatment with herceptin and herceptin/Lipoplex.
Lattová E; Tomanek B; Bartusik D; Perreault H
J Proteome Res; 2010 Mar; 9(3):1533-40. PubMed ID: 20063903
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of human MCF-7 breast carcinoma with antibody, cationic lipid and hyaluronic acid using ex vivo assays.
Bartusik D; Tomanek B; Lattová E; Perreault H; Fallone G
J Pharm Biomed Anal; 2010 Jan; 51(1):192-201. PubMed ID: 19709839
[TBL] [Abstract][Full Text] [Related]
4. Ex vivo assays of CEM cells cultured and treated in the three dimensional cultures.
Bartusik D; Tomanek B; Lattová E; Perreault H; Fallone G
Biomed Pharmacother; 2010 Jul; 64(6):390-5. PubMed ID: 20347572
[TBL] [Abstract][Full Text] [Related]
5. Application of 19F magnetic resonance to study the efficacy of fluorine labeled drugs in the three-dimensional cultured breast cancer cells.
Bartusik D; Tomanek B
Arch Biochem Biophys; 2010 Jan; 493(2):234-41. PubMed ID: 19900396
[TBL] [Abstract][Full Text] [Related]
6. MUC1* is a determinant of trastuzumab (Herceptin) resistance in breast cancer cells.
Fessler SP; Wotkowicz MT; Mahanta SK; Bamdad C
Breast Cancer Res Treat; 2009 Nov; 118(1):113-24. PubMed ID: 19415485
[TBL] [Abstract][Full Text] [Related]
7. Detection of fluorine labeled herceptin using cellular (19)F MRI ex vivo.
Bartusik D; Tomanek B
J Pharm Biomed Anal; 2010 Mar; 51(4):894-900. PubMed ID: 19896315
[TBL] [Abstract][Full Text] [Related]
8. Darpp-32 and its truncated variant t-Darpp have antagonistic effects on breast cancer cell growth and herceptin resistance.
Gu L; Waliany S; Kane SE
PLoS One; 2009 Jul; 4(7):e6220. PubMed ID: 19593441
[TBL] [Abstract][Full Text] [Related]
9. Presence of HER4 associates with increased sensitivity to Herceptin in patients with metastatic breast cancer.
Sassen A; Diermeier-Daucher S; Sieben M; Ortmann O; Hofstaedter F; Schwarz S; Brockhoff G
Breast Cancer Res; 2009; 11(4):R50. PubMed ID: 19624808
[TBL] [Abstract][Full Text] [Related]
10. 3, 3'-Diindolylmethane enhances the effectiveness of herceptin against HER-2/neu-expressing breast cancer cells.
Ahmad A; Ali S; Ahmed A; Ali AS; Raz A; Sakr WA; Rahman KM
PLoS One; 2013; 8(1):e54657. PubMed ID: 23372748
[TBL] [Abstract][Full Text] [Related]
11. Herceptin resistance database for understanding mechanism of resistance in breast cancer patients.
Ahmad S; Gupta S; Kumar R; Varshney GC; Raghava GP
Sci Rep; 2014 Mar; 4():4483. PubMed ID: 24670875
[TBL] [Abstract][Full Text] [Related]
12. A novel humanized anti-HER2 antibody conjugated with MMAE exerts potent anti-tumor activity.
Yao X; Jiang J; Wang X; Huang C; Li D; Xie K; Xu Q; Li H; Li Z; Lou L; Fang J
Breast Cancer Res Treat; 2015 Aug; 153(1):123-33. PubMed ID: 26253944
[TBL] [Abstract][Full Text] [Related]
13. Development and characterization of a preclinical ovarian carcinoma model to investigate the mechanism of acquired resistance to trastuzumab.
Luistro LL; Rosinski JA; Bian H; Bishayee S; Rameshwar P; Ponzio NM; Ritland SR
Int J Oncol; 2012 Aug; 41(2):639-51. PubMed ID: 22580986
[TBL] [Abstract][Full Text] [Related]
14. Differential sensitivities of trastuzumab (Herceptin)-resistant human breast cancer cells to phosphoinositide-3 kinase (PI-3K) and epidermal growth factor receptor (EGFR) kinase inhibitors.
Chan CT; Metz MZ; Kane SE
Breast Cancer Res Treat; 2005 May; 91(2):187-201. PubMed ID: 15868447
[TBL] [Abstract][Full Text] [Related]
15. Quantitative proteomics with siRNA screening identifies novel mechanisms of trastuzumab resistance in HER2 amplified breast cancers.
Boyer AP; Collier TS; Vidavsky I; Bose R
Mol Cell Proteomics; 2013 Jan; 12(1):180-93. PubMed ID: 23105007
[TBL] [Abstract][Full Text] [Related]
16. Both t-Darpp and DARPP-32 can cause resistance to trastuzumab in breast cancer cells and are frequently expressed in primary breast cancers.
Hamel S; Bouchard A; Ferrario C; Hassan S; Aguilar-Mahecha A; Buchanan M; Quenneville L; Miller W; Basik M
Breast Cancer Res Treat; 2010 Feb; 120(1):47-57. PubMed ID: 19301121
[TBL] [Abstract][Full Text] [Related]
17. MALDI-TOF-MS analysis of sialylated glycans and glycopeptides using 4-chloro-α-cyanocinnamic acid matrix.
Selman MH; Hoffmann M; Zauner G; McDonnell LA; Balog CI; Rapp E; Deelder AM; Wuhrer M
Proteomics; 2012 May; 12(9):1337-48. PubMed ID: 22589184
[TBL] [Abstract][Full Text] [Related]
18. Proteomic profiling of Trastuzumab (Herceptin(R))-sensitive and -resistant SKBR-3 breast cancer cells.
DI Cara G; Marengo G; Albanese NN; Marabeti MR; Musso R; Cancemi P; Pucci-Minafra I
Anticancer Res; 2013 Feb; 33(2):489-503. PubMed ID: 23393341
[TBL] [Abstract][Full Text] [Related]
19. [Trastuzumab (herceptin) for the medical treatment of breast cancer].
Bayoudh L; Afrit M; Daldoul O; Zarrad M; Boussen H
Tunis Med; 2012 Jan; 90(1):6-12. PubMed ID: 22311450
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antibody glycosylation analysis: a contract research organization perspective in the frame of batch release or comparability support.
Delobel A; Cantais F; Catrain A; Dereux E; Van Vyncht G
Methods Mol Biol; 2013; 988():115-43. PubMed ID: 23475717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
